Lv6
2308 积分 2024-04-22 加入
Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in breast cancer therapeutics
1天前
待确认
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
1个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
2个月前
已完结
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
2个月前
已完结
Gastric Cancer
2个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
6个月前
已完结
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
6个月前
已完结
[Mechanism and management of cancer chemotherapy-induced gastrointestinal mucosa damage]
10个月前
已完结
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
10个月前
已完结
Oncology Dose Optimization: Tailored Approaches to Different Molecular Classes
10个月前
已关闭
皖公网安备34019202002308
